# Tafinlar (dabrafenib mesylate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dabrafenib

> The FDA approved Tafinlar (dabrafenib mesylate), sponsored by NOVARTIS AG (NVS), on March 16, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Tafinlar (dabrafenib mesylate) |
| Codes |  |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | priority review |

## Timeline

### January 28, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202806 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20220128, review_priority STANDARD; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202806%22

### May 27, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202806 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20220527, review_priority STANDARD; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202806%22

### June 22, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202806 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20220622, review_priority PRIORITY; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202806%22

### March 16, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA217514 ORIG-1 (New Combination and New Formulation or New Manufacturer): submission_status AP, submission_status_date 20230316, review_priority PRIORITY; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217514%22

### March 16, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202806 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20230316, review_priority PRIORITY; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202806%22

### August 31, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202806 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20230831, review_priority PRIORITY; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202806%22

### March 7, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202806 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20250307, review_priority STANDARD; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202806%22
- openFDA Drugs@FDA: "NDA217514 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20250307, review_priority STANDARD; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217514%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dabrafenib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tafinlar (dabrafenib mesylate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dabrafenib

```bibtex
@misc{secapidev_pdufa_dabrafenib_20261116,
  title        = {Tafinlar (dabrafenib mesylate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dabrafenib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dabrafenib_20261116","title":"Tafinlar (dabrafenib mesylate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dabrafenib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
